Oncology Institute, INC Form 4 insider transactions

The Oncology Institute, Inc. Director Brad Hively reported exercising a substantial number of stock options and subsequently selling common stock, following a transition agreement that led to the cancellation of his unvested options.

Jeffrey Langsam, Chief Clinical Officer of Oncology Institute, Inc., reported the acquisition of 57,380 shares of common stock through the vesting of Restricted Stock Units.

M33 Growth I L.P., a significant shareholder in Oncology Institute, Inc. (TOI), has sold a portion of its holdings, reducing its direct ownership while maintaining indirect ownership through related entities.

Daniel Virnich, CEO of Oncology Institute, sold 20,388 shares of common stock on May 21, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Yale Podnos, Chief Medical Officer of Oncology Institute, Inc., sold 1,801 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Robert Ross Carter, CFO of Oncology Institute, Inc., sold 1,601 shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Jeremy Castle, Chief Operating Officer of Oncology Institute, sold shares of common stock on May 21, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Brad Hively, a director at Oncology Institute, files an amended Form 4 to correct the number of shares and warrants acquired in a private placement.

Yale Podnos, Chief Medical Officer of Oncology Institute, reports the acquisition and disposal of common stock and RSU awards.

Robert Ross Carter, CFO of Oncology Institute, reports the acquisition of 197,368 shares of Class A Common Stock.

Chief Operating Officer of Oncology Institute, Jeremy Castle, reports acquisition and disposal of common stock and RSU awards.

Daniel Virnich, CEO of Oncology Institute, reports acquiring and disposing of common stock on March 31, 2025, according to a Form 4 filing.

M33 Growth I L.P. purchased units consisting of common stock and warrants in Oncology Institute, Inc., resulting in changes in beneficial ownership.

Daniel Virnich, CEO of Oncology Institute, purchased shares and warrants in a private placement, increasing his holdings in the company.

Yale Podnos, Chief Medical Officer of Oncology Institute, acquires shares and warrants through a private placement, increasing his holdings in the company.

Mark L. Pacala, a director of Oncology Institute, acquired shares and warrants through a private placement, increasing his beneficial ownership.

Karen Marie Johnson, a director at Oncology Institute, purchased shares and warrants through a private placement, increasing her holdings in the company.

Director Brad Hively purchased shares and warrants of Oncology Institute, Inc. through a private placement.

Oncology Institute's Chief Operating Officer, Jeremy Castle, acquired common stock and warrants through a private placement, as detailed in a Form 4 filing with the SEC.

Robert Ross Carter, CFO of Oncology Institute, purchased shares and warrants in a private placement transaction.

Richard Barasch, a director of Oncology Institute, acquired shares and warrants through a private placement, increasing his beneficial ownership.

Daniel Virnich, CEO of Oncology Institute, sold 10,261 shares of common stock on March 19, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Yale Podnos, Chief Medical Officer of Oncology Institute, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Robert Ross Carter, CFO of Oncology Institute, sold 1,150 shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Robert Ross Carter, CFO of Oncology Institute, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Oncology Institute's Chief Operating Officer, Jeremy Castle, sold 1,130 shares of common stock to cover tax obligations related to vesting restricted stock units.

Director Brad Hively of Oncology Institute, Inc. reports the forfeiture of 353,450 shares and the acquisition of 300,000 shares through open market purchases.

Director Richard Barasch of Oncology Institute, Inc. acquired 80,000 shares of common stock through restricted stock units.

Mark L. Pacala, a director at Oncology Institute, acquired 50,000 shares of restricted stock on November 22, 2024, which will vest at the 2025 annual shareholder meeting.

Director Anne McGeorge of Oncology Institute, Inc. acquired 56,000 restricted stock units, which will vest at the 2025 annual shareholder meeting.